Raltegravir: The evidence of its therapeutic value in HIV-1 infection
网页2010年6月15日 · Raltegravir (Isentress ®), in combination with other anti-retroviral agents, is indicated for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and drug-resistant HIV-1 viral strains. It is formulated as its potassium salt and is available as film-coated tablets containing 434.4 mg ...
Raltegravir: The First HIV Type 1 Integrase Inhibitor
网页2009年4月1日 · Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. Clinical trials have demonstrated that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated in HIV-1–infected individuals.
Raltegravir - Wikipedia
网页Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [5] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following …
Raltegravir: Uses, Interactions, Mechanism of Action - DrugBank …
网页2010年9月14日 · Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the …
Novel Perspectives on the Design and Development of a Long …
网页2023年5月18日 · For instance, a phase 2b clinical trial demonstrated that long-acting intramuscular injection of two ARVs (rilpivirine and cabotegravir), administered every 4 or 8 weeks, was as effective as daily oral therapy in maintaining viral suppression over 96 weeks .
Raltegravir: the first HIV-1 integrase strand transfer ... - PubMed
网页Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well as heavily pretreated HIV-infected patients failin ….
Raltegravir with Optimized Background Therapy for Resistant …
网页2008年7月24日 · Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.
Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in …
网页2011年3月22日 · Raltegravir is the first integrase strand transfer inhibitor approved for the treatment of HIV-1 infection. As the first agent in this new class of antiretroviral therapies, raltegravir has demonstrated safety and efficacy in treatment-naive as well as heavily pretreated HIV-infected patients failing therapy with multidrug-resistant virus.
Raltegravir: Its use in the Treatment of HIV Infection
网页2009年4月3日 · Raltegravir (MK-0518, Isentress®) is the first inhibitor of a novel target, the HIV integrase enzyme, to be approved in many countries for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adults who have evidence of viral replication and have HIV-1 strains resistant to multiple ant...
Clinical pharmacology profile of raltegravir, an HIV-1 ... - PubMed
网页Raltegravir is an HIV-1 integrase inhibitor approved to treat HIV infection in adults in combination with other antiretrovirals. Data from healthy volunteers demonstrate that raltegravir is rapidly absorbed with a mean half-life of approximately 7 to 12 hours, with steady state achieved in approxima ….
跳至内容